Improves skin elasticity and firmness
RV-8451, differentiated oral, muscle-preserving GLP-1 candidate for obesity Recent Highlights: In February 2026, Rivus stated it was entering a pivotal year, advancing HU6 in the AMPLIFY Phase 2 MASH trial while preparing the first clinical trial for RV-8451, its muscle-preserving oral GLP-1 candidate, designed to address the muscle-loss criticism leveled at existing GLP-1 therapies
Snack: Three-quarter cup of plain Greek yogurt with a tablespoon of chia seeds and a handful of blueberries
While generally regarded as safe for short-term use in healthy individuals, the long-term safety of routine digestive enzyme supplementation in patients on GLP-1 therapy has not been systematically evaluated
Mix the routine with other activities
Vitamin D advice The evidence relating to the health effects of serum Vitamin D levels, sunlight exposure and Vitamin D intake remains inconclusive